A recently-published, independent, peer-reviewed, international study in Current Urology measured reliability and transparency of online medical information for people with prostate cancer and their caregivers, and found the NCCN Guidelines for Patients to be one of the most trustworthy resources.
Early GP referrals are likely to lead to cancer patients surviving longer, a study by King's College London has found.
Death rates from prostate cancer are predicted to fall in 2020 in the EU, largely due to better diagnosis and treatment, according to new research published in the leading cancer journal Annals of Oncology. Death rates from lung and pancreatic cancers continue to rise in women. A total of 1.4 million people are predicted to die from all cancers by the end of 2020.
Once a cancer patient's tumors develop resistance to chemotherapy, the prognosis can be poor. However, inhibiting a key gene involved in multidrug resistance, MDR1, has not improved outcomes. A new study offers a reason, revealing unintended downstream effects on immune system cells.
Researchers from Ghent University, Belgium, together with researchers from the University of Turku, Finland, have developed a new method for biomarker discovery of urological cancers. The method enables timely diagnosis and treatment of cancer. Urological cancers include e.g. prostate, bladder and kidney cancers.
In an article published in Nature Communications, Moffitt Cancer Center researchers provide a closer look at a mathematical model and data showing that individual patient alterations in the prostate-specific antigen (PSA) biomarker early in cancer treatment can predict outcomes to later treatment cycles of adaptive therapy.
Data for 950,000 black, white, Asian and Hispanic patients in the U.S. diagnosed with prostate, ovarian, breast, stomach, pancreatic, lung, liver, esophageal, or colorectal cancers were analyzed to examine differences by race and ethnicity in stage at diagnosis, use of therapy, overall survival and cancer-specific survival.
Purdue University scientists have created a new therapy option that may help halt tumor growth in certain cancers such as prostate, which is among the most common types of cancer in men.
A subset of patients with metastatic prostate cancer and specific markers of immune activity responded well to treatment with immune checkpoint inhibitors, according to results of a Phase II trial.
Data for nearly 230,000 men were used in this study to examine variations in survival in prostate cancer by geographic areas in the United States.